LABSOLUTIONS offers a comprehensive suite of genetic tests, allowing providers to personalize treatment plans. Coupling the latest laboratory technologies with highly trained scientists and counselors keeps our clients cutting-edge.
Pharmacogenomics is the study of how human genetic variation affects an individual’s response to drug therapies. Understanding a patient’s genetic background allows a physician to predict how a prescribed drug will relate with that patient, giving the clinician insight into not only clinical efficacy, but also potential undesired drug reactions.
- Biologic enzymes found in our liver act upon certain target substrates and then trigger a metabolic chain reaction.
- This data can then be used to help physicians avoid drugs that would be inefficiently metabolized and guide them towards drugs that use more robust metabolic pathways.
FDA studies estimate that 7% of hospitalized patients have a serious adverse drug reaction with a fatality rate of 0.32%.
By isolating and examining the regions of a patient’s DNA that code for the enzymes of interest, we can provide the following answers:
How well does the patient metabolize drugs and what personal factors are being used to aid in drug selection?
RESPONSE™ acts as a lifelong prescribing roadmap, steering the provider towards drugs that are metabolized efficiently and away from those that are not.
Is there a system to identify when a patient is taking a medication that is poorly suited for them?
RESPONSE™ acts as a safeguard, protecting both physician and patient from undesirable adverse drug reactions.
How do enzymes interact with their targets and how does the patient's genetic makeup affect these interactions?
Enzymes modify drugs into their active and inactive metabolites. A person’s genetic makeup may seriously affect how well certain enzymes perform.
How can a physician mitigate drug-drug interactions when a patient is prescribed multiple medications?
RESPONSE™ flags potentially dangerous interactions between drugs and often suggests suitable alternatives.
There are more than 2,216,000 serious ADRs in hospitalized patients, causing over 106,000 deaths annually.
Annual ADR Deaths
Patients have differences in DNA that impact drug metabolism which may increase their likelihood of an adverse drug reaction:
More than 85% of the population have detectable variations in their DNA that increase their risk for adverse drug reactions.
Adverse drug reactions are the 4th leading cause of death nationwide with more than 8.6 million cases reported annually.
The FDA highlights pharmacogenomics data for more than 130 prescription medications, indicating their strong support for testing.
Who To Test?
LabSolutions advises pharmacogenomics testing for patients that meet one or more of the following conditions:
Patients that experience less than optimal results from prescribed medications.
Patients with a personal or family history of adverse drug reactions in response to certain medications.
Polypharmacy patients; those taking multiple prescription medications for multiple chronic conditions.
Comprehensive Pharmacogenomic Analysis